White House Fact Sheet: Research-First Approach to Cannabis Reform

In late December 2025, the White House released an important fact sheet on cannabis reform. It introduced a research-first approach, marking a clear change in national policy. This plan, officially called the White House Cannabis Research Policy, focuses on expanding scientific research on cannabis and related products. It also aims to improve patient access and build solid evidence to guide future drug policy decisions.

This detailed fact sheet goes with the executive action called “Increasing Medical Marijuana and Cannabidiol Research,” signed by President Donald J. Trump on December 18, 2025. While it does not legalize cannabis at the federal level right away, the policy shows a shift in federal thinking. It puts science and patient care first, moving away from strict rules left over from the prohibition era.

Why the White House Cannabis Research Policy Matters?

For many years, federal law classified cannabis as a Schedule I drug under the Controlled Substances Act. This label meant it was seen as having no accepted medical use and a high risk of abuse. Because of this, serious scientific research was very limited. Medical institutions were unable to fully study cannabis, including both its potential benefits and its possible risks.

The White House Cannabis Research Policy aims to change this by focusing on evidence-based science. It acknowledges that many states and millions of patients already use cannabis for medical reasons. The policy suggests that federal rules should catch up with real-world use and the growing body of research.

Key Elements of the White House Cannabis Research Policy

The White House Cannabis Research Policy focuses on three main priorities. Together, they show a shift toward science-based reform, patient safety, and long-term evidence rather than fast legal changes.

Expanding Federal Cannabis Research

Rescheduling Marijuana to Remove Research Barriers

A major part of the policy is expanding federally approved cannabis research. The executive order directs the Attorney General to speed up the process of moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. This shift would formally recognize medical use and remove strict rules that have limited research for decades, according to the White House.

What Schedule III Means for FDA-Approved Studies

Schedule III is far less restrictive than Schedule I. It places cannabis in the same category as other medications with accepted medical use and lower abuse risk. This change would allow the FDA and research institutions to approve and conduct clinical studies more easily, helping scientists study cannabis with fewer legal obstacles.

Federal Evidence Supporting Medical Use

The fact sheet highlights federal findings that support medical cannabis use. These include treatment for chronic pain, chemotherapy-related nausea, vomiting, and appetite loss. The White House also notes that more than 40 states and Washington, D.C. already operate medical cannabis programs that are serving millions of patients.

Improving Safe Access to Cannabidiol and Hemp-Derived Products

Regulatory Gaps in the CBD Market

The policy also looks at problems in the CBD market. Even though CBD is not a controlled substance, unclear federal rules and uneven product quality have raised safety concerns. Many patients and consumers feel confused because oversight is weak and standards vary from one product to another.

Push for Clear Federal Standards on CBD Products

The White House is asking senior officials to work with Congress to create clearer rules for full-spectrum CBD products. These efforts include setting THC limits per serving, improving labeling requirements, and cutting down on unsafe or misleading products in the market.

Balancing Consumer Safety With Patient Access

These actions would help balance access with safety. The goal is to protect public health while letting patients use regulated cannabinoid products confidently. Clear rules would help consumers make better choices and lower the risks from poorly regulated CBD products.

Long-Term Scientific Focus and Real-World Evidence

Moving Cannabis Policy From Enforcement to Science

Unlike past federal policies that focused on enforcement, the White House Cannabis Research Policy puts science first. It moves cannabis reform toward research, health data, and evidence-based decisions instead of punishment or political arguments.

Using Real-World Data to Study Cannabis Effects

Federal agencies, like the Department of Health and Human Services, are being asked to use real-world evidence. This means studying patient results, population health trends, and how people actually use cannabis outside of controlled labs.

Building Evidence for Future Health and Regulatory Decisions

The policy focuses on long-term research. Studies will look at lasting health effects, risks for young people, and real medical benefits. The White House wants to create a strong scientific base to guide future rules, medical advice, and public health decisions.

What does this mean for Patients, Scientists, and the Cannabis Industry?

For Patients and Medical Providers

The White House Cannabis Research Policy will help to fill a major gap. Many American patients use cannabis for medical reasons, but doctors often lack federal guidance on safe dosing or long-term effects because research has been limited. By rescheduling cannabis and expanding studies, the policy could help doctors make better clinical decisions, offer more treatment options, and support the development of FDA-approved therapies. 

However, groups like Americans for Safe Access warn that rescheduling by itself won’t give full legal access or protect patients at the federal level. Without more action from Congress, patients could still face legal barriers or discrimination.

For Scientists and Universities

Research institutions have struggled for years to study cannabis because it’s been classified as Schedule I. By directing agencies to speed up rescheduling and expand research, the White House policy could open the door to new clinical trials, better data systems, and more collaboration.

This change builds on earlier laws, like the Medical Marijuana and Cannabidiol Research Expansion Act of 2022, which made it easier to register and conduct formal research studies.

Read our recent article to know how marijuana rescheduling could unlock tax breaks for researchers.

For the Cannabis Industry

The policy doesn’t legalize recreational cannabis, but it could still help the industry in other ways.

By setting clear research standards and rules for products, especially medical ones, it creates more certainty. Rescheduling may also remove unfair tax penalties, such as those under Section 280E, providing cannabis businesses with a fairer chance compared to other industries.

What Comes Next?

The White House Cannabis Research Policy represents a major shift toward science and public health in federal cannabis rules.

Important actions, like rescheduling, still need to go through official procedures under the Controlled Substances Act, which could take months or more. Even so, the policy shows a federal commitment to evidence-based approaches that put patient needs and strong research first.

By aligning with decades of changing state laws and public opinion, it could help build political agreement. In summary, this policy is a key step toward science-driven cannabis reform in the U.S. and sets a standard for future rules and legal changes.

Click here to know more about the legal impacts of rescheduling on the cannabis industry.